Global Anti-D Immunoglobulin Market Anticipated to Reach US$ 497.9 Million by 2031

According to a recent market study published by Growth Market Reports, titled, “Anti-D Immunoglobulin Market by Dose Strength, Packaging Type, and Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 276.2 Million in 2022 and is projected to expand at a growth rate of 7.0% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/5969

Anti-D immunoglobulin (a concentrated antibody preparation) is made from the clear part of the blood, called plasma, collected from blood donors. Anti-D injections are given to the Rh-negative mothers to treat rhesus disease. Rhesus disease occurs if there are mixed blood types of RhD-positive and RhD-negative.

It occurs in the case of a pregnant woman when the mother is RhD negative, and the baby is RhD positive and people who have received mismatched transfusion (RhD negative child or adult who has accidentally received RhD positive blood). Anti-D immunoglobulins suppresses the immune response and antibody formation by Rh-D-negative mothers to RhD-positive RBCs of children thus preventing isoimmunization.

The anti-D immunoglobulin market has been fragmented based on dose strength and packaging type. By dose strength, the global anti-D immunoglobulin market is categorized as 100 mcg, 50 mcg, 300 mcg, and others. In terms of packaging type, the market is bifurcated as vials and prefilled syringe. On the basis of regions, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.

The Coronavirus disease 2019 (COVID-19) pandemic highlighted economic disparities, global interdependence, and governance challenges. However, the COVID-19 outbreak has a slightly negative impact on the consumption rate of anti-D immunoglobulins, as the pregnant mothers isolated themselves during the pandemic. The pandemic disrupted various businesses and supply chains. The production chain for these therapeutic agents was reduced. Priority was given only to the urgent cases.

As per Growth Market Reports industry analyst, Ruchika Sharma, “Expanding healthcare and R&D activities are expected to contribute to the growth of the global anti-D immunoglobulin market. Advances in research and development, treatment for rhesus disease, and the rising prevalence of Rh-negative pregnancies are contributing to the expansion of the anti-D immunoglobulin market.

Demand for Anti-D Immunoglobulin is projected to grow in the coming years, due to the rising cases of hemolytic diseases in fetus and newborns. Total of ~13 Mn doses are required annually to prevent sensitization of RhD. However, ~4 Mn doses are administered annually. Developing countries such as India and China have a huge population base, hence, the demand is projected to expand in the forecast period”.

A supply chain is a network between manufacturers and suppliers to produce and distribute a specific product to the final buyers. This network includes different people, regulatory bodies, entities, information, and resources. Entities in the supply chain include raw material suppliers, manufacturers, logistics, warehouses, pharmacies, finance, distributors, and customers. Supply chain management is an essential part of any business.

Patients suffering from rhesus disease are expected to suffer from miscarriage, if the supply chain of anti-D immunoglobulin is hampered. Companies/manufacturers have tie-ups with the distributors and hospitals, which helps them to expand their business at the required places.

Key Takeaways from the Study:

• Players in the global Anti-D Immunoglobulin market include BHARAT SERUMS AND VACCINES LIMITED, CSL Behring AG, Grifols, S.A., Octapharma AG, Kamada Pharmaceuticals, KEDRION SPA, OCEAN PHARMACEUTICAL, PV Pharma, Taj Pharmaceuticals Limited, Zydus Group. CSL Behring AG, Grifols, KEDRION SPA, and Octapharma AG held a major market share of the anti-D immunoglobulin market in 2022.

• Rising approval of medications with different routes of administration and increasing prevalence of gastroparesis cases are contributing to the growth of the global Anti-D Immunoglobulin market.

• In terms of dose strength, the global anti-D immunoglobulin market is categorized as 100 mcg, 50 mcg, 300 mcg, and others. The 300 mcg segment is projected to account for a substantial share of the anti-D immunoglobulin market during the forecast period. 300 mcg is one of the most commonly available dose strength for the treatment of rhesus disease and immune thrombocytopenic purpura for patients. Rhesus disease is a two-dose treatment (prenatal and post-natal care) where in majority of the cases, 300 mcg is administered in the patients.

• In terms of regions, the global Anti-D Immunoglobulin market is divided into North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. North America is projected to account for a significant share of the anti-D immunoglobulin market during the forecast period, owing to the increasing facilities for treatment and well-established healthcare system in the region. Europe holds a large share of the market, due to rising R&D activities in the region.

Report Anti-D Immunoglobulin Market Scope:

Target Audience:

• Supply-side: Manufacturers and distributors

• Demand Side: Hospitals and clinics

• Regulatory Side: Concerned government authorities and other approved regulatory bodies

• Associations and Industry Bodies: Food and Drug Administration (FDA), National Health Service (NHS), and World Health Organization (WHO)